about
Clinical trials update from the European Society of Cardiology-Heart Failure meeting 2015: AUGMENT-HF, TITRATION, STOP-HF, HARMONIZE, LION HEART, MOOD-HF, and renin-angiotensin inhibitors in patients with heart and renal failureThe effects of short-term omission of daily medication on the pathophysiology of heart failure.Interatrial shunt devices for heart failure with normal ejection fraction: a technology update.Sarcopenia in patients with heart failure with preserved ejection fraction: Impact on muscle strength, exercise capacity and quality of life.A meta-analysis of the therapeutic effects of glucagon-like Peptide-1 agonist in heart failure.ECHO and magnetic resonance imaging in a patient with high bleeding risk and ventricular perforation: a case report and literature review.Medical management of stable coronary atherosclerosis.Old and newer biomarkers in heart failure: from pathophysiology to clinical significance.Does cirrhotic cardiomyopathy exist? 50 years of uncertainty.Case selection for cardiac resynchronization in atrial fibrillation.Telemonitoring in heart failure: Big Brother watching over you.Clinical trials in patients with heart failure and preserved left ventricular ejection fraction.Remote telemonitoring for patients with heart failure: might monitoring pulmonary artery pressure become routine?Update on management of heart failure with preserved ejection fraction.New pharmacological approaches in heart failure therapy: developments and possibilities.Takotsubo syndrome in the paediatric population: a case report and a systematic review.This patient is not breathing properly: is this COPD, heart failure, or neither?Pharmacological and Non-pharmacological Treatment for Decompensated Heart Failure: What Is New?Prevalence and Outcomes of Anemia and Hematinic Deficiencies in Patients With Chronic Heart Failure.The obesity paradox in type 2 diabetes mellitus: relationship of body mass index to prognosis: a cohort study.The relationship of QRS morphology with cardiac structure and function in patients with heart failure.[Betablockers in patients with heart failure and atrial fibrillation].If home telemonitoring reduces mortality in heart failure, is this just due to better guideline-based treatment?Prescribing patterns to optimize heart rate: analysis of 1,000 consecutive outpatient appointments to a single heart failure clinic over a 6-month period.Prognostic significance of ultrasound-assessed jugular vein distensibility in heart failure.IVC diameter in patients with chronic heart failure: relationships and prognostic significance.Why does CRT reduce the risk of arrhythmias?Clinical trials update from the American Heart Association meeting 2010: EMPHASIS-HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF, and PROTECT.The in vitro stability of novel cardiovascular and sepsis biomarkers at ambient temperature.Global longitudinal strain in patients with suspected heart failure and a normal ejection fraction: does it improve diagnosis and risk stratification?Left atrial function measured by cardiac magnetic resonance imaging in patients with heart failure: clinical associations and prognostic value.Cardiac dysfunction in cirrhosis is not associated with the severity of liver disease.Time to Take the Failure Out of Heart Failure: The Importance of Optimism.Prognostic value of psychosocial factors for first and recurrent hospitalizations and mortality in heart failure patients: insights from the OPERA-HF study.Exploring quality of life in patients with and without heart failure.Is Swimming Safe in Heart Failure? A Systematic Review.Clinical and prognostic relationships of pulmonary artery to aorta diameter ratio in patients with heart failure: a cardiac magnetic resonance imaging study.Prevalence, predictors, and prognostic implications of PR interval prolongation in patients with heart failure.Tachycardia-induced cardiomyopathy in pregnancy.Cardiac Dysfunction, Congestion and Loop Diuretics: their Relationship to Prognosis in Heart Failure.
P50
Q26796378-BF517F4A-7280-42A9-A62F-0E36828EE25EQ30355107-3AED7D7F-5707-48B4-9C6A-6A217FA75326Q33812836-AA8EBC09-ED4D-459F-9C0A-A89B427E8355Q36084695-1D22707C-A2CA-4107-B104-7527AD3D9EF3Q36090588-77D13967-7F76-49D6-935D-C52D6732EF81Q37907230-D3F8E39C-9B62-4F93-B4F0-7DA7FE08F67DQ38083007-AFE1D4AE-AAEA-4BC9-9941-A835079DF40AQ38121014-D2165958-898F-458A-A54D-A8FE1A550F7FQ38133308-BFFBB5F2-4EE8-40D5-8FE1-66A75AB84C5CQ38140245-5E8F6A7D-472A-40DA-A8D2-9D9DE3A2FE8FQ38223913-0F63FDD1-25C4-41DF-ABF8-456FAB50913DQ38224337-E4E5E00B-BD18-4A59-AC93-83EF2F650F12Q38225325-C84FE962-B0ED-4FEF-AEF0-B05AB2279FBDQ38324929-7982EA80-757A-4280-B545-55C548B509CBQ38759494-D785AA2F-E949-4B9E-AA6E-BA362E43ECF4Q38965722-505AF0BF-84AC-412D-AE92-954EBC92AC0EQ39232408-42458AF6-5220-4E7F-8FF4-8EB9CFC4802DQ39249844-B18F0426-4E58-4279-B581-6319AE70E4DBQ39579991-17614710-D52A-4673-B41E-5B1E0F843B16Q40979404-0B465996-B03F-45DC-9A9E-3EC8E7044265Q41028024-3A02993B-5A80-49D5-AAFE-F00319FDEC06Q41121223-86AB829D-5563-48F4-B88F-3C84E3D9350BQ41232264-DE25A70B-5762-4CA8-882D-7C9CA558EEF0Q41481550-B056DAE4-B7B1-47A7-9225-D503EEF81F8EQ41719153-1670B9BE-FE17-4B1C-8DF3-516572156F92Q44521675-CAF3AA95-3164-42D2-960E-A4DA5B54899AQ44709996-A83CC9BD-14C3-403B-A985-AAAE4BE31FC8Q44825076-F72E6BF0-F718-41FD-9414-ED1B3F1FBE7DQ44899727-5785839D-0543-483C-B701-DC3ADD21A7C2Q44969281-5871BEDA-4447-4E87-856F-6B64E9AFF1E6Q45912425-66D30BF0-2355-4FD8-B4CA-78ED966E2B61Q45982442-921A1A5A-9A96-44BC-ADFA-19E5963681ABQ47313952-B457BB4C-D331-4F33-8957-B4A8F471DCA9Q47563208-9A9D1C48-F0A6-4A11-95D5-647A350AFEF5Q47928443-94C01C7F-5C76-41D0-B388-C54497789743Q47947062-038A9DC9-BF7F-43D5-92C7-82AFE89F99B8Q48186551-27B11BD4-5268-4483-A1FB-9E37B1516B2FQ48335944-B3E7AD47-9285-405B-A4EC-DBA024E73735Q48420053-FF1F5056-E59C-435F-BCF9-33D5FB635DF7Q48437939-0D2E01D9-2533-44AA-A193-005F946633BA
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Pierpaolo Pellicori
@ast
Pierpaolo Pellicori
@en
Pierpaolo Pellicori
@es
Pierpaolo Pellicori
@nl
Pierpaolo Pellicori
@sl
type
label
Pierpaolo Pellicori
@ast
Pierpaolo Pellicori
@en
Pierpaolo Pellicori
@es
Pierpaolo Pellicori
@nl
Pierpaolo Pellicori
@sl
prefLabel
Pierpaolo Pellicori
@ast
Pierpaolo Pellicori
@en
Pierpaolo Pellicori
@es
Pierpaolo Pellicori
@nl
Pierpaolo Pellicori
@sl
P1053
N-1880-2013
P106
P1153
35485204000
P21
P31
P3829
P3835
pierpaolo-pellicori
P496
0000-0001-7175-0464